GlobeNewswire - Industry News on Coal

Sandoz Canada completes its 5th biosimilar launch with new biosimilar Hyrimoz? (adalimumab)

Tue, 16 Feb 2021 13:00 GMT

BOUCHERVILLE, Quebec, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Sandoz Canada Inc. announced today the launch of Hyrimoz^?(adalimumab injection, reference biologic drug: Humira^?), which was authorized for sale in Canada by Health Canada on November 4, 2020 as one of the four Sandoz biosimilars to be authorized in Canada in the last 11 months. Hyrimoz^? is indicated for the treatment of nine (9) of the twelve life-threatening or serious debilitating conditions in adults and children covered by the reference medicine*, including the treatment of rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn’s disease, ulcerative colitis, hidradenitis suppurativa, psoriasis and adult uveitis.

Sandoz Canada lance son 5ème biosimilaire Hyrimoz? (adalimumab)

Tue, 16 Feb 2021 13:00 GMT

BOUCHERVILLE, Québec, 16 févr. 2021 (GLOBE NEWSWIRE) -- Sandoz?Canada inc. a annoncé aujourd’hui le lancement d’Hyrimoz^? (injection d’adalimumab, médicament biologique de référence?: Humira^?), approuvé pour la vente à l’échelle nationale par Santé?Canada le 4?novembre?2020. Il s’agit du quatrième biosimilaire de Sandoz autorisé au Canada au cours des 11?derniers mois. Hyrimoz^?est indiqué pour le traitement de neuf?(9) des douze?(12)?affections qui sont potentiellement mortelles ou graves et débilitantes chez les adultes et les enfants et qui sont visées par le médicament de référence*, notamment pour traiter la polyarthrite rhumato?de, l’arthrite juvénile idiopathique polyarticulaire, l’arthrite psoriasique, la spondylarthrite ankylosante, la maladie de Crohn chez l’adulte, la colite ulcéreuse, l’hidradénite suppurée, le psoriasis et l’uvéite chez l’adulte.

Sandoz Canada launches the first generic versions of two original drugs: PrSandoz? Posaconazole and PrSandoz? Silodosin

Tue, 26 Jan 2021 13:00 GMT

BOUCHERVILLE, Quebec, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Sandoz Canada Inc. announced today the launch of ^PrSandoz^? Posaconazole and ^PrSandoz^? Silodosin, making Sandoz the first company to offer posaconazole and silodosin generics on the Canadian market. The launch of ^PrSandoz^? Silodosin follows a patent litigation whereby the Federal Court ruled that the Sandoz product does not infringe a patent for this drug. These new Sandoz products make these treatments more accessible to patients and their healthcare professionals and reduce pressure on the healthcare system.

Sandoz Canada lance les premières versions génériques de deux médicaments originaux : PrSandoz? Posaconazole et PrSandoz? Silodosin

Tue, 26 Jan 2021 13:00 GMT

BOUCHERVILLE, Québec, 26 janv. 2021 (GLOBE NEWSWIRE) -- Sandoz Canada?Inc. annonce aujourd’hui le lancement de ^PrSandoz^? Posaconazole et ^PrSandoz^?Silodosin, faisant de Sandoz la première entreprise à offrir des génériques de posaconazole et silodosine sur le marché canadien. Le lancement de ^PrSandoz^?Silodosin fait suite à un litige de brevet suivant lequel la Cour fédérale a statué que le produit de Sandoz ne contrefaisait pas un brevet portant sur ce médicament. Ces nouveaux produits de Sandoz permettent de rendre ces traitements plus accessibles aux patients et à leurs professionnels de la santé et de réduire la pression sur le système de santé.

Canada Coal Announces Ayurcann Receipt of Amendment to Standard Processing Licence to Allow for Sales

Wed, 20 Jan 2021 16:05 GMT

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.

Sandoz Canada receives authorization from Health Canada to launch new biosimilar Hyrimoz? (adalimumab)

Thu, 17 Dec 2020 15:45 GMT

BOUCHERVILLE, Quebec, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Sandoz Canada Inc. announced today that Health Canada has authorized Hyrimoz^?(adalimumab injection, reference biologic drug: Humira^?) on November 4, 2020 for marketing in Canada. Hyrimoz^? has been approved for the treatment of the same nine (9) life-threatening or serious debilitating conditions in adults and children as the reference medicine*, including the treatment of rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn’s disease, ulcerative colitis, hidradenitis suppurativa, psoriasis and adult uveitis.

Sandoz Canada re?oit l’autorisation de Santé Canada de lancer le nouveau biosimilaire Hyrimoz? (adalimumab)

Thu, 17 Dec 2020 15:45 GMT

BOUCHERVILLE, Québec, 17 déc. 2020 (GLOBE NEWSWIRE) -- Sandoz?Canada?Inc. a annoncé aujourd’hui que Santé?Canada a homologué Hyrimoz^? (injection d’adalimumab, médicament biologique de référence?: Humira^?) le 4?novembre?2020 pour être commercialisé au Canada. Hyrimoz^? a été approuvé pour le? traitement des mêmes neuf?(9)?affections potentiellement mortelles ou graves et débilitantes chez les adultes et les enfants que le médicament de référence*, notamment pour traiter la polyarthrite rhumato?de, l’arthrite juvénile idiopathique polyarticulaire, l’arthrite psoriasique, la spondylarthrite ankylosante, la maladie de Crohn chez l’adulte, la colite ulcéreuse, l’hidradénite suppurée, le psoriasis et l’uvéite chez l’adulte.

Death of R. Bruce Duncan, Canada Coal Inc.’s Chief Executive Officer

Mon, 16 Nov 2020 15:10 GMT

MISSISSAUGA, Ontario, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Canada Coal Inc. (the “Company”) (NEX: CCK):

Silver Elephant Announces C$6.0 Million Bought Deal Public Offering of Common Shares

Tue, 20 Oct 2020 20:32 GMT

VANCOUVER, British Columbia, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Silver Elephant Mining Corp. (“Silver Elephant” or the “Company”) (TSX: ELEF, OTCQX:SILEF, Frankfurt:1P2N) is pleased to announce that it has entered into an agreement with? Mackie Research Capital Corporation as lead underwriter and sole bookrunner (the “Lead Underwriter”), on behalf of a syndicate of underwriters, including Canaccord Genuity Corp. and Sprott Capital Partners LP (collectively with the Lead Underwriter, the “Underwriters”), pursuant to which the Underwriters have agreed to purchase, on a bought‐deal basis, 15,000,000 common shares of the Company (the “Common Shares”) at a price of C$0.40 per Common Shares for gross proceeds of C$6,000,000 (the “Offering”).

Sandoz Canada launches two new biosimilars Ziextenzo? and Riximyo?

Wed, 19 Aug 2020 12:00 GMT

BOUCHERVILLE, Quebec, Aug. 19, 2020 (GLOBE NEWSWIRE) -- Sandoz Canada Inc. announces it has reached a negotiated agreement with the Pan-Canadian Pharmaceutical Alliance (pCPA) and launched Ziextenzo^?(pegfilgrastim, reference biologic drug: Neulasta^?) and Riximyo^? (rituximab, reference biologic drug: Rituxan^?) in Canadian hospitals and pharmacies. This follows the recent approval of the two biosimilars by Health Canada.

Sandoz Canada lance deux nouveaux biosimilaires?: Ziextenzo? et Riximyo?

Wed, 19 Aug 2020 12:00 GMT

BOUCHERVILLE, Québec, 19 août 2020 (GLOBE NEWSWIRE) -- Sandoz Canada Inc. annonce la conclusion d’une entente avec l’Alliance pancanadienne pharmaceutique (APP) et le lancement de Ziextenzo^? (pegfilgrastim, médicament biologique de référence?: Neulasta^?) et de Riximyo^? (rituximab, médicament biologique de référence?: Rituxan^?) dans les h?pitaux et les pharmacies du Canada. Ceci donne suite à l’autorisation récemment obtenue de Santé Canada pour les deux biosimilaires.

Sandoz Canada Launches The Biosimilars Generation

Thu, 25 Jun 2020 12:00 GMT

BOUCHERVILLE, Quebec, June 25, 2020 (GLOBE NEWSWIRE) -- Sandoz, a global leader in generic and biosimilar medicines, announced today the launch in Canada of The Biosimilars Generation campaign to help Canadians better understand the benefits of biosimilars, their proven safety and efficacy, and the opportunities they present to the healthcare system to realize savings and increase access to innovative new medicines.

Sandoz Canada lance La Génération Biosimilaires

Thu, 25 Jun 2020 12:00 GMT

BOUCHERVILLE, Québec, 25 juin 2020 (GLOBE NEWSWIRE) -- Sandoz, un chef de file mondial en matière de médicaments génériques et de biosimilaires, a annoncé aujourd’hui le lancement au Canada de sa campagne La Génération Biosimilaires. Cette campagne vise à aider les Canadiens à mieux comprendre les avantages, l’innocuité et l’efficacité avérés des biosimilaires, ainsi que l’accès accru à de nouveaux médicaments novateurs et les économies qu’ils peuvent représenter pour notre système de santé.

Sandoz Canada receives Health Canada approval to launch two oncology biosimilars: Ziextenzo? and Riximyo?

Tue, 09 Jun 2020 12:00 GMT

BOUCHERVILLE, Quebec, June 09, 2020 (GLOBE NEWSWIRE) -- Sandoz Canada Inc., a division of Novartis AG, announced today that Health Canada has approved Ziextenzo^?(pegfilgrastim, reference biologic drug: Neulasta^?) and Riximyo^? (rituximab, reference biologic drug: Rituxan^?) for marketing in Canada.

Sandoz?Canada re?oit l’approbation de Santé?Canada pour le lancement de deux biosimilaires en oncologie?: Ziextenzo? et Riximyo?

Tue, 09 Jun 2020 12:00 GMT

BOUCHERVILLE, Québec, 09 juin 2020 (GLOBE NEWSWIRE) -- Sandoz Canada?Inc., une division de Novartis?AG, annonce aujourd’hui que Santé?Canada a approuvé Ziextenzo^?(pegfilgrastim, biologique de référence?: Neulasta^?) et Riximyo^? (rituximab, biologique de référence?: Rituxan^?) pour commercialisation au Canada.

Coney Island To Open June 12 With New Operating Procedures

Mon, 08 Jun 2020 13:23 GMT

CINCINNATI, June 08, 2020 (GLOBE NEWSWIRE) -- Coney Island will open for the 2020 season on Friday, June 12. In order to protect its guests and employees, Coney Island will implement new operating procedures, enhanced sanitation practices, and new guest policies based on recommendations and guidelines from both leading health experts and state and local agencies.

Pepcap Announces Resignation of Director

Fri, 03 Apr 2020 16:46 GMT

VANCOUVER, British Columbia, April 03, 2020 (GLOBE NEWSWIRE) -- Pepcap Resources, Inc. (TSXV-WAV.H) (“Pepcap” or the “Company”) announces that Gek Suan Margaret Wee has resigned as a member of the board of directors of the Company (the “Board”). The Board has accepted the resignation of Ms. Wee and wishes to thank her for her contributions to the Company.

Canada Coal Terminates Proposed Business Combination With Mijem Inc.

Tue, 18 Feb 2020 21:15 GMT

VANCOUVER, British Columbia, Feb. 18, 2020 (GLOBE NEWSWIRE) -- Canada Coal Inc. (the “Company” or “Canada Coal”), (TSX-V: CCK.H) announces that it has terminated its proposed business combination with Mijem Inc. (“Mijem”) first announced on November 20^th, 2019. Despite having received shareholder approval to the proposed transaction with Mijem at an annual and special meeting of Canada Coal’s shareholders held on February 7^th, 2020, regrettably Mijem was not able to raise the required $1.85 million minimum in concurrent financing required to complete the business combination.

Largest Aquaglide pool obstacle course in the United States comes to Coney Island

Wed, 05 Feb 2020 15:00 GMT

Climb, jump, slide, bounce, and challenge your friends at the Challenge Zone

Climb, jump, slide, bounce, and challenge your friends at the Challenge Zone

Pepcap Reports Revocation of Cease Trade Order

Tue, 28 Jan 2020 18:37 GMT

VANCOUVER, British Columbia, Jan. 28, 2020 (GLOBE NEWSWIRE) -- Pepcap Resources, Inc. (TSXV-WAV.H) (“Pepcap” or the “Company”) is pleased to announce the revocation of the cease trade order (the “CTO”) issued by the British Columbia Securities Commission (the “BCSC”) on February 1, 2019 following the Company’s application for a revocation of the CTO and the BCSC having completed a review of Pepcap’s continuous disclosure filings. The Company will now proceed with the completion of the arm’s length sale (the “Andika Sale”) by Asia Mining Management B.V. (“Asia Mining”), a 51% owned subsidiary of Pepcap, of all of the shares of PT Krida Darma Andika held by Asia Mining (for further details, please refer to the Company’s news releases dated September 13, 2018 and October 23, 2019). Upon completion of the Andika Sale, the Company will be evaluating other business opportunities and will update the shareholders as to its progress.